Statute Details
- Title: Health Products (Therapeutic Products) Regulations 2016
- Act Code: HPA2007-S329-2016
- Type: Subsidiary legislation (SL)
- Enabling Act: Health Products Act (HPA)
- Status: Current version (as at 27 Mar 2026)
- Commencement: SL 329/2016 (commencement date not shown in the extract provided)
- Key subject areas: licensing (manufacture/import/wholesale), supply controls, product presentation, registration of therapeutic products, post-market duties, and exceptions
- Key provisions (from extract): Regulation 2 (definitions), Regulation 3 (scope/exclusions), and the overall Part structure from Parts 1–9
- Related legislation (as provided): Dental Registration Act 1999; Health Products Act; Healthcare Services Act 2020; Medical Registration Act 1997; Pharmacists Registration Act 2007
What Is This Legislation About?
The Health Products (Therapeutic Products) Regulations 2016 (“TP Regulations”) are Singapore’s detailed regulatory rules for therapeutic products—covering how such products are manufactured, imported, supplied, presented to the public, and registered with the competent authority. In practical terms, the Regulations translate the broader policy goals of the Health Products Act into day-to-day compliance obligations for industry and healthcare actors.
The Regulations are designed to protect public health by ensuring that therapeutic products meet safety, quality, and information standards before they enter the market and after they are supplied. They also create a structured licensing regime for key activities (manufacture, import, wholesale supply) and impose record-keeping, reporting, and recall-related duties. Where full licensing or registration would be impractical, the Regulations provide carefully bounded exceptions (for example, for certain healthcare service licensees, licensed retail pharmacies, named patients, personal imports, and emergency therapeutic products).
Although the extract provided does not reproduce the full text of each regulation, the headings and numbering show a comprehensive framework. A practitioner should read the Regulations as a compliance instrument: it sets out who must be licensed or registered, what must be done (and documented), what information must be provided to consumers and regulators, and what happens when products or applications do not meet statutory requirements.
What Are the Key Provisions?
1) Preliminary scope and definitions (Parts 1 and early provisions). The Regulations begin with standard legal architecture: Regulation 1 provides citation and commencement; Regulation 2 contains definitions; and Regulation 3 sets the scope. The extract indicates that the Regulations do not apply to certain therapeutic products that are “clinical research material” (as defined in the Regulations). This is important for practitioners because it delineates the boundary between regulated commercial therapeutic products and materials used in clinical research contexts.
2) Manufacture and import licensing (Part 2). Part 2 establishes licensing requirements for manufacturing and importing therapeutic products. Regulation 4 sets out requirements for the issue of a manufacturer’s licence, while Regulation 5 sets out requirements for the issue of an importer’s licence. These provisions typically require applicants to demonstrate capability, compliance readiness, and appropriate controls over product quality and regulatory obligations.
Regulation 6 specifically addresses the import of therapeutic products containing psychotropic substances. This is a targeted control reflecting the heightened risks and regulatory scrutiny associated with controlled substances. Practitioners should treat this as a “special regime” within the broader import licensing framework: even where a general importer’s licence exists, additional conditions and compliance steps may be triggered for psychotropic substances.
3) Supply controls, including wholesale and retail (Part 3). Part 3 is one of the most operational parts of the Regulations. It is divided into: (i) requirements for purposes of section 17; (ii) wholesale supply; (iii) retail supply of registered therapeutic products; and (iv) other supply requirements.
For wholesale supply, the Regulations include provisions on exports of psychotropic substances (Regulation 8), export of codeine cough preparations (Regulation 9), and wholesale of therapeutic products containing “Second Schedule ingredients” (Regulation 10). These provisions indicate that certain ingredient categories are subject to additional controls—likely reflecting abuse potential, diversion risk, or special public health considerations.
For retail supply, the Regulations distinguish between different categories of medicines and different modes of supply. Regulation 11 covers supply by retail sale of prescription-only medicine; Regulation 12 covers supply by administration of prescription-only medicine; and Regulation 13 covers supply by retail sale of pharmacy-only medicine. Regulation 14 imposes restrictions on supply by retail sale of codeine cough preparations, which again signals a controlled substance/abuse-risk category. Regulation 15 addresses supply of “general sale list” medicine by retail sale vending machine, showing that even lower-risk medicines are regulated when sold through automated channels.
Part 3 also includes supply record and dispensing requirements. Regulation 16 requires records of supply of prescribed therapeutic products, and Regulation 17 governs supply by dispensing therapeutic products. These provisions are crucial in enforcement and litigation contexts because they define what records must exist, what they must show, and how supply activities are evidenced.
4) Product presentation and information duties (Part 4). Part 4 addresses how therapeutic products are presented to the market. Regulation 19 requires compliance with “trade descriptions.” Regulation 20 requires information to be provided with therapeutic products. Regulation 21 provides corrective measures where there is contravention of trade descriptions or failure to provide prescribed information. For practitioners, this is a key area for consumer protection and regulatory compliance: incorrect labelling, misleading trade descriptions, or incomplete mandatory information can trigger enforcement action and may also create downstream liability in civil claims.
5) Registration of therapeutic products and exclusivity (Part 5). Part 5 sets out the registration framework. Regulation 22 provides requirements for registration. Regulation 23 addresses whether a therapeutic product is subject to patent, and Regulation 24 provides for cancellation of registration of a therapeutic product subject to patent dispute. Regulation 24A introduces a prescribed time for cancellation of registration for non-payment of a retention fee—an important administrative compliance point for registrants.
Regulation 25 creates offences for making false declarations, which is a high-risk compliance area in applications and supporting documentation. Regulations 26–27 provide protection for confidential supporting information relating to innovative therapeutic product applications, but also specify circumstances where such protection does not apply. Regulation 28 concerns disclosure of information on applications for registration. Regulation 29 addresses registration exclusivity, which is likely intended to balance innovation incentives with regulatory transparency and market access.
6) Post-market and ongoing compliance duties (Part 6). Part 6 imposes continuing obligations on manufacturers, importers, wholesalers, and registrants. Division 1 contains general duties: Regulation 30 requires compliance with enforcement requirements; Regulation 31 requires records of manufacture; Regulation 32 requires records of receipt and supply; Regulation 33 requires records of defects and adverse effects; Regulation 34 requires reporting defects and adverse effects; and Regulation 35 requires notification to the Authority concerning recall. Together, these provisions create a full lifecycle compliance model—from production and distribution to pharmacovigilance and recall.
Division 2 imposes duties specific to licensees, including duties of licensed manufacturer (Regulation 36), licensed importer (Regulation 37), licensed wholesaler (Regulation 38), and a “responsible person” (Regulation 39). Regulation 40 provides an offence for contravention of duties, and Regulation 41 addresses changes affecting a licence—important for corporate restructuring, changes in premises, or changes in responsible personnel.
Division 3 imposes duties specific to registrants: Regulation 42 concerns changes concerning registered therapeutic product; Regulation 43 requires information on validity of data submitted or considered by the Authority; Regulation 44 requires submission of benefit-risk evaluation reports; and Regulation 45 imposes a duty to carry out a risk management plan. These provisions are central to maintaining registration status and ensuring that the Authority has up-to-date evidence about ongoing benefit-risk profiles.
7) Exceptions: when licensing/registration may not be required (Part 7 and Part 8A). Part 7 provides exceptions allowing manufacture, import, and wholesale of therapeutic products without licence. The extract shows multiple categories: specified healthcare service licensees (Regulations 46–47), licensed retail pharmacies (Regulations 48–49), named patients (Regulations 50–51), personal imports (Regulation 52), wholesale for export (Regulation 53), and other exceptions including import by licensed manufacturers (Regulation 54), wholesale of self-manufactured therapeutic products (Regulation 55), and wholesale to ships or aircraft (Regulation 56). Regulation 57 addresses therapeutic products for research or non-clinical purposes.
Part 8 provides exceptions for supply without registration (Regulations 58–60), including prescribed exceptions, supply under contractual agreement with a licensed manufacturer (Regulation 59), and previously registered therapeutic products (Regulation 60). Part 8A introduces an emergency exception (Regulation 60A) for manufacture, import, and supply of emergency therapeutic products. For practitioners, these exceptions are often where disputes arise: the factual circumstances must fit the regulatory category precisely, and documentation is critical to demonstrate eligibility for the exception.
8) Miscellaneous compliance instruments (Part 9). Part 9 includes certification and quality surveillance provisions. Regulations 61–64 address certifications of therapeutic products intended for export and manufacturing/distribution standards. Regulation 65 concerns product quality surveillances, Regulation 66 addresses non-compliant therapeutic products, and Regulation 67 concerns confidential information. These provisions support international trade compliance and internal quality governance.
How Is This Legislation Structured?
The TP Regulations are structured in nine Parts, with divisions within key Parts:
Part 1 (Preliminary): citation/commencement, definitions, and scope (including exclusions such as clinical research material).
Part 2 (Manufacture and Import): licensing for manufacturers and importers, including special controls for psychotropic substances.
Part 3 (Supply): supply requirements across wholesale and retail channels, including record-keeping and dispensing requirements, and licensing requirements for wholesalers.
Part 4 (Presentation): trade descriptions, mandatory information, and corrective measures.
Part 5 (Registration): registration requirements, patent-related considerations, cancellation mechanics, confidentiality and disclosure, and registration exclusivity.
Part 6 (Duties and Obligations): ongoing compliance duties for licensees and registrants, including pharmacovigilance, recall notification, risk management, and reporting.
Part 7 (Exceptions—without licence): multiple categories of persons/contexts where activities may be carried out without a manufacturer/importer/wholesaler licence.
Part 8 and Part 8A (Exceptions—without registration; emergency): supply exceptions and an emergency therapeutic product regime.
Part 9 (Miscellaneous): certifications, quality surveillance, handling of non-compliant products, and confidentiality.
Who Does This Legislation Apply To?
The TP Regulations apply primarily to persons and entities involved in the lifecycle of therapeutic products in Singapore: manufacturers, importers, wholesalers, retail suppliers, and registrants of therapeutic products. The licensing provisions in Part 2 and Part 3 indicate that commercial operators must obtain appropriate licences to carry out regulated activities, subject to exceptions.
Healthcare service licensees and licensed retail pharmacies may fall within specific exception categories allowing certain activities without a licence (Part 7). Named patients and personal importers may also be covered by limited exceptions, but only where the facts align with the regulatory conditions. Registrants—typically the parties responsible for the registered therapeutic product—are subject to ongoing duties including benefit-risk evaluation reporting and risk management plan obligations (Part 6, Division 3).
Why Is This Legislation Important?
The TP Regulations are important because they operationalise Singapore’s therapeutic product regulatory system. For practitioners, the Regulations are not merely “administrative”: they create enforceable duties that affect licensing validity, registration status, and compliance risk. Non-compliance can lead to offences (including false declarations and contraventions of duties), cancellation of registration (including for non-payment of retention fees), and regulatory action relating to labelling and information failures.
From a litigation and advisory perspective, the Regulations’ emphasis on records (manufacture, receipt and supply, defects and adverse effects, and supply records) and reporting (defects/adverse effects and recall notifications) is particularly significant. These provisions shape the evidential trail in investigations and disputes. A practitioner advising a manufacturer, importer, wholesaler, or registrant should therefore treat record-keeping and reporting workflows as core compliance infrastructure, not optional best practice.
Finally, the Regulations’ architecture of exceptions is a double-edged sword: it enables practical access in defined circumstances (e.g., named patients, emergency therapeutic products, certain healthcare service activities), but also creates a compliance boundary that must be carefully managed. Where an exception is invoked, practitioners should ensure that documentation and factual circumstances align with the specific regulatory category, because regulators may scrutinise whether the exception conditions were met.
Related Legislation
- Health Products Act (HPA)
- Healthcare Services Act 2020
- Medical Registration Act 1997
- Pharmacists Registration Act 2007
- Dental Registration Act 1999
Source Documents
This article provides an overview of the Health Products (Therapeutic Products) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.